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In the interim, we have used our resources to identify differences in ovarian cancer risk between Israeli Jewish women and American women in order to focus our explorations. Our results to date (4) show that factors protective in general (oral contraceptive use, bearing children, tubal ligation, hysterectomy, no talc use) are protective in both the US and Israeli population. However, the magnitude of the protection appears greater for American women than for Israeli women. Our findings together with the greater percentage of BRCA1/2 carriage among women in Israel would suggest that the rate of ovarian cancer would be greater in Israel than in the US. To the contrary, the rate of ovarian cancer is remarkably similar in the two countries. We conclude that it is likely that there is some genetic and/or environmental factor that may provide protection to Israeli Jewish women. We are hopeful that the DNA we receive from Israel will work and will allow us to examine the possibility of genetic modifying factors. Further evidence for our conclusion comes from data in which we show that among Jewish women with ovarian cancer, the percent of carriers of a BRCA1/2 mutation is greater for US women than for Israeli Jewish women (46% vs. 25%). This suggests an environmental factor.
Much attention has focused on the role of inflammation in ovarian cancer risk and survival. Thus, we pilot tested our laboratory assays for a set of polymorphisms in inflammation-associated genes (ILIA-4845 T/G, ILIA-M889 T/C, IL1B-3957 G/A, IL6-M174 C/G, IL10-M819 T/C, IL1O-M1082 C/T, IL18-M137 G/C) in a convenience sample of 141 ovarian cancer cases. Our assays were successful and our preliminary data suggested that the ILI 8-M137 SNP may be associated with tumor stage and histologic subtype, suggesting that this polymorphism may influence disease phenotype and survival. It further suggests that exposure to inflammation-associated factors may alter the risk of ovarian cancer in women with a certain genetic makeup. 4 
KEY RESEARCH ACCOMPLISHMENTS:
-showed that oral contraceptive use and bearing children are as protective in BRCAI/2 carriers as they are in women in general -showed that the incidence rates of ovarian cancer are similar in Israel and in Western Pennsylvania (USA), despite the greater prevalence of BRCAI/2 mutations in Israel. This suggests that Israeli women more often engage in protective behaviors (or US women more often engage in risk-associated behaviors) or that protective factors are more protective in the Israeli population.
showed that oral contraceptives, bearing children, having a tubal ligation and having a hysterectomy protect against ovarian cancer in a population at a genetically high risk (Jewish Israeli women) as well as in the general American population, while talc use and greater BMI is a risk factor for both populations.
showed that OC use and bearing children are more protective in the US population, suggesting that unknown genetic and/or environmental factors exist for ovarian cancer -showed that Jewish women with ovarian in the US are more likely to be BRCAI/2 carriers than Jewish women with ovarian cancer in Israel, suggesting that BRCAI/2 is more penetrant in the US. This supports the existence of an unknown environmental factor. -showed that genetic variants in inflammation-associated genes may affect ovarian cancer phenotype, suggesting that these variants may prove promising for investigating the genetic factors that might affect BRCAI/2 penetrance. These data further suggest that inflammation-associated environmental exposures (e.g., NSAID use) may be fruitful areas of investigation for factors that alter ovarian cancer risk in BRCAI/2 carriers.
breast-feeding have consistently been shoWn to reduce and ovarian cancer in BRCA1/2 carriers [9] but this was ovarian cancer risk among women in general [6, 7] . less than 10%. Unfortunately, because subject links Tubal ligation has also been shown to reduce ovarian from the original studies to this study were not cancer risk [6, 8] . However, little is known about the maintained, we were unable to identify which cases impact of these factors on ovarian cancer risk in included in this study were also included in the previous BRCA1/2 mutation carriers. In a case-control study report of OCs and ovarian cancer [9] . comparing 207 women with hereditary ovarian cancer Moslehi et al. [11] (the hospital-based study) classified to 161 of their unaffected sisters without the disease, a woman as Jewish if three out of four grandparents OC use was less common among women with the were Jewish. Questions about place of birth of parents disease [9] . This suggests that OC use may reduce the and grandparents further identified Ashkenazi women in risk of ovarian cancer in women with a mutation in the that study. In Lu et al. [13] (one of the population-based BRCA1 or BRCA2 genes. However, the results of that studies), a woman was considered to be Jewish if she study have been questioned, because the BRCA1/2 indicated that her childhood religious upbringing was carrier status of some of the sisters was unknown. This Jewish. For the other two sources of subjects, a woman unknown data can potentially invalidate the findings, was considered to be Jewish if she classified herself as More recently, a case-control study of Israeli Jewish Jewish on medical records. women found that the risk of ovarian cancer among Specific descriptions of each study methodology are carriers of a BRCA1 or BRCA2 mutation decreases provided in the original publications [11] [12] [13] and are with each birth but not with increased duration of use summarized in Table 1 . Briefly, Moslehi et al. [11] used of oral contraceptives [10] . These conflicting data medical records to identify 465 Jewish women with suggest the need to further investigate the potential ovarian cancer. Of these, 80 women were dead, 33 of OCs as a chemopreventive agent among women women were found not to have invasive disease on with a BRCA1/2 mutation. pathology review, 98 women were unreachable, and 49 In this study, we aimed to evaluate the potential women refused to participate. The remaining 208 benefit associated with OC use among women at high (44.7%) women completed an in-person interview and risk for ovarian cancer because they carry a mutated provided a blood sample. Ness et al. [12] identified all BRCA1 or BRCA2 gene. We also sought to determine women age 20-69 diagnosed with ovarian cancer in the the benefit or risk associated with other reproductive Delaware Valley between 1994 and 1998. Of the 957 factors, including childbearing, breastfeeding, and tubal eligible women, 69 were too ill to participate, 15 were ligation in these women.
untraceable, and 92 refused to participate. Fourteen physicians did not consent to their patients' participating, for a total of 767 (80.1%) eligible women who Methods completed an in-person interview. For the study presented here, we used medical records to identify Subjects successfully the religious affiliation of 437 of the 767 women, 46 of whom were Jewish, and we used banked Because of the high prevalence of three BRCA1/2 pathology specimens (normal tissue blocks) to deterfounder mutations among Ashkenazi Jewish women mine BRCA1/2 carrier status of 36 of these women. Lu with invasive epithelial ovarian cancer [11] , we limited et al. [13] used tumor registries to identify 1080 women our study to Jewish women with epithelial ovarian with ovarian cancer in eastern Massachusetts and New cancer and with no prior history of breast cancer. Data Hampshire between May 1992 and March 1997. Of the on subjects were pooled from four sources: two popu-1080 women, 203 had died or were unreachable, 126 lation-based case-control studies of epithelial ovarian were not contacted because their physician denied cancer in the United States (100 cases) [12, 13] , a permission, 136 women declined participation, and 52 hospital-based study of Jewish women with epithelial had non-epithelial ovarian cancer. The remaining 563 ovarian cancer among 11 centers in North America and (52%) women were interviewed, during which time they Israel (208 cases) [11] , and a genetic counseling center in provided a blood sample and answered questions about Chicago (14 cases). The Chicago clinic had been one of their childhood religious upbringing. Of the 563 womthe sites for the hospital-based study, but the 14 en, 54 identified Jewish as the religion of their upincident, invasive cases included in this analysis were bringing. in addition to those participating in the original study.
Each study obtained written informed consent from There was some overlap between cases included in the participants and was approved by the appropriate current study and those in the previous report of OCs institutional review boards. Exposure information, BRCA1/2 mutation status of the three BRCA1/2 founder mutations. Regardless of and data quality the technique employed, all mutations were confirmed by direct sequencing of DNA. Non-carriers were defined From each study source, data were requested on the use as women with none of the three mutations (for the of OCs, including age at first and last use, and duration studies employing only the Ashkenazi panel) and no of use. Data were also obtained on number of live other detected mutations (for subjects from Moslehi births, age at first and last live birth, and total duration et al. [11] ). BRCA1 carriers were defined as women with of breastfeeding. We further requested information on either the 185delAG or the 5382insC in BRCA1. Women other factors including age at menarche, body mass with the 6174delT in BRCA2 were defined as BRCA2 index, history of hysterectomy and history of tubal mutation carriers. ligation. Because data on age at menopause and All subject data submitted for the pooled analysis hormone replacement therapy were inconsistent among were anonymous. Approval for the pooled analysis was the studies, we were not able to include them in our obtained from the University of Pittsburgh Institutional analyses. We obtained details of tumor histology on all Review Board. subjects, and we restricted our analyses to invasive ovarian cancers of the epithelial type. All data were Study design and statistical analyses checked for internal consistency and corrections or clarifications were requested from the original investi-To determine whether carriers and non-carriers differed gators when necessary.
in OC use, parity, breast-feeding, and tubal ligation, we All subjects were screened for the three Ashkenazi employed a case-only study design [15] . In a case-only founder mutations (185delAG and 5382insC in BRCA1 study, cases with the genotype (carriers) form the and 6174delT in BRCA2) Mutation analysis was 'pseudo-cases' and cases without the susceptibility performed by the original study investigators using genotype (non-carriers) form the 'pseudo-control' several established detection techniques, including het-group. The two groups are compared with respect to eroduplex analysis, single-strand conformation analysis the prevalence of each exposure. The odds ratio (OR) and allele-specific oligonucleotide hybridization. In ad-reflects the association between the exposure and the dition, Moslehi et al. [11] tested all subjects for muta-genotype (assuming independence of genotype and tions in exon 11 of BRCA1 and exons 10 and 11 of exposure). If this ratio is different from one, then the BRCA2 using the protein-truncation test [14] . Truncat-relative risk associated with the exposure differs for ing mutations in these exons represent about 70% of the carriers and non-carriers. For a protective factor such as BRCA1/2 mutations found to date [11] . No women from OC use, childbearing and breastfeeding in ovarian that study included in the analysis reported here were cancer, an OR greater than one indicates that the factor found to have any BRCA1/2 mutations other than one was more prevalent among the carriers ('pseudo-cases'); thus, the factor provides less protection to carriers than expected, BRCA1 carriers with invasive tumors were to non-carriers. Conversely, an OR of less than one diagnosed at a significantly earlier average age than nonindicates that the factor was less prevalent among the carriers (51.2 versus 57.5 years, p = 0.001). In contrast, carriers, and suggests that the factor provides greater BRCA2 carriers were diagnosed at later ages than nonprotection for carriers than for non-carriers, carriers (60.8 versus 57.5 years), although this difference To control for potentially confounding effects of was not significant. The difference in age at diagnosis other factors, we used unconditional logistic-regression between BRCA1 carriers and BRCA2 carriers, however, analyses and included as covariates age at diagnosis and was significant (p < 0.001). year of birth as continuous terms. Age at diagnosis was Only 11.7% of non-carriers reported a family history included in all models because univariate analyses of ovarian cancer, compared to 16.1% of BRCAI showed a significant difference between carriers and carriers (p = 0.39) and 29.0% of BRCA2 carriers non-carriers. Because the studies differed in the time (p =0,017 for comparison to non-carriers). Similarly, period in which they were performed, year of birth was non-carriers were less likely to report a family history of included in order to control for secular trends in OC breast cancer (15.2% for non-carriers versus 22.6% for use, parity and breastfeeding. However, there were no BRCA1 carriers and 35.5% for BRCA2 carriers). The differences in results between analyses including year of difference between BRCA2 carriers and the non-carriers birth and those' excluding the variable. We therefore was significant (p = 0.011). present the most parsimonious model in this paper. To Table 3 compares reproductive factors among carriers check the reasonableness of pooling data fiom diverse and non-carriers. After adjusting for possible confoundsources, we calculated a Mantel-Haenszel test for ers, there were no significant differences between the heterogeneity for all major results. In none of the groups for age at menarche, ages at first and last live associations between BRCA status and reproductive birth, or breastfeeding. There was also no difference in factors did we find statistically significant heterogeneity the percent of nulliparous women between carriers and among subject source. In addition, models that included non-carriers. However, parous BRCAJ carriers reported a variable for study site did not differ in results from fewer live births than parous non-carriers. The average models excluding the variable; thus, the final models number of live births among parous women was 2.5 presented in this paper do not include a variable for among non-carriers, but only 2.1 among BRCAJ carristudy site. All analyses were performed with the ers (OR= 0.61, 95%CI = 0.39-0.95, adjusted for age at STATA statistical software package (STATA Corpora-diagnosis, tubal ligation and duration of OC use). tion, Release 5.0) and all p values given are from two-Although parous BRCA2 carriers also reported fewer sided tests.
live births than non-carriers, the difference between We analyzed all cases with complete exposure data. parous BRCA2 carriers and non-carriers was not Because one of the parent studies [11] noted a difference significant. in age at onset between BRCA1 and BRCA2 carriers, and
Interestingly, compared to non-carriers, BRCA1 carbecause univariate analyses showed other differences in riers were more likely to report having had a tubal risk factors between BRCA1 and BRCA2 carriers for the ligation (25.0 versus 10.2%, OR= 3.67, 95%CI = 1.55-entire study population, we analyzed the data for 8.70 adjusted for age at diagnosis, number of live births BRCA I and BRCA2 carriers both jointly and separately. and OC use). BRCA2 carriers were less likely to report a history of tubal ligation compared to non-carriers, but the difference was not significant. However, the differResults ence between BRCA1 and BRCA2 carriers was significant (p < 0.05). No differences in hysterectomy were Table 1 presents a summary of the subjects participating found between carriers and non-carriers. in this study from the four parent studies. A total of 322
We compared additional characteristics of oral concases of epithelial ovarian cancer in Jewish women were traceptive use between carriers and non-carriers identified. Of these, complete exposure data were (Table 4) . No significant differences were found in ever obtained on 305 cases and BRCA1/2 status was con-use of OCs or in duration of OC use. However, BRCA1 firmed on 295 cases. Of the 295 cases, invasive histology carriers were likely to have begun using OCs at a later was confirmed on all but 53 cases, for a total of 242 mean age than non-carriers (24.0 versus 23.2 years of cases included in this analysis.
age, OR= 1.15, 95%CI= 1.01-1.30 adjusted for age at The characteristics of the 64 subjects with a BRCA1 diagnosis, number of live births, tubal ligation and OC mutation, the 31 subjects with a BRCA2 mutation, and duration). BRCAI carriers were also more likely to the 147 non-carriers are presented in Table 2 . As report recent use of OCs. The mean interval from last Missing data are as follows: four subjects (2 BRCA-, 2 BRCA I+): family history of breast or ovarian cancers; I BRCA2 + subject: BMI; I BRCA-subject: age at first and last birth.
Among women who had a live birth; b Among ever users. Each row represents a separate model. All models were adjusted for age at diagnosis, number of live births (continuous variables) and OC use and history of tubal ligation (yes/no), except for those noted by (b), which were not adjusted for number of live births, and those noted by ('), which were not adjusted for tubal ligation. ORs in bold are significant at the p < 0.05 level.
d Among women who had a live birth.
use to diagnosis was 19.6 years for BRCA1 carriers and tubal ligation and OC duration). The differences in age 21.4 years for non-carriers (OR = 0.89, 95%CI = 0.79-at first OC use or recent OC use between BRCA2 0.99 adjusted for age at diagnosis, number of live births, carriers and non-carriers were not significant. Each row represents a separate model. Each model is adjusted for age at diagnosis, year of birth, number of live births, OC duration (continuous variables) and history of tubal ligation, except for that noted by (b), which was adjusted for OC duration. ORs in bold are significant at the p < 0.05 level.
Among ever users.
Discussion difference in age at first use and recency of use between BRCA1 carriers and non-carriers, these differences were We pooled data on Jewish women with invasive ovarian small and may be due to chance. We failed to demoncancer from four sources in order to determine whether strate a similar association between early OC use or there were differences in OC use, childbearing, breast-recency of OC use for BRCA2 carriers. Again, this may feeding and tu6al ligation between BRCA1/2 mutation be due to differences in the effects of OC use in BRCA2 carriers with invasive ovarian cancer and non-carriers carriers, or it may be due to the small number of BRCA2 with the disease. carriers in our study.
SWe found no difference in the percent of nulliparous
We further found that the protection associated with women between carriers and non-carriers, although early OC use differed between BRCA1 and BRCA2, parous BRCA1 carriers had experienced fewer live although this difference may be due to the small number births than non-carriers (2.1 versus 2.5). This suggests of BRCA2 carriers. Notably, the direction of the ORs that the effect of bearing children .is similar for both for the age and timing data among BRCA2 carriers was BRCA1 carriers and non-carriers. It is possible that the opposite to that of the ORs for the BRCA1 carriers, earlier age at diagnosis among BRCA1 carriers may suggesting that the difference between the two groups partially explain fewer live births in that group. How-may be real and not an artifact of sample size. ever, in our population-based case-control study [16] , These results are in contrast to those of Modan et al. healthy controls with a mean age of 49.5 years had on [101 who reported that the use of OC provided no average 2.8 live births. This suggests that the earlier age protection to Israeli Jewish BRCA1/2 carriers. While we of diagnosis cannot fully explain the observed reduced cannot exclude the possibility that our finding is due to parity. Moreover, our analyses showed a similar finding chance, we believe that there are differences between the (fewer live births compared to non-carriers) for parous two studies that may explain these disparate findings. In BRCA2 carriers, despite that fact that compared with particular, the duration and frequency of use of OCs non-carriers and BRCA1 carriers, BRCA2 carriers had a were far less in the Israeli population than in the later age at diagnosis. We are careful to note, however, population studied here. Moreover, there may be that this result failed to reach statistical significance, differences in OC formulations between the two popupossibly due to the small number of BRCA2 carriers in lations. In addition, as discussed below, the differences our study.
between the study designs (case-control versus caseWith regards to breastfeeding, we found no differences only) and our small sample size may account for the between BRCA1/2 carriers and non-carriers. Thus, the different findings. effect of breastfeeding on ovarian cancer risk appears to Interestingly, BRCA1 carriers were more likely to be similar for both carriers and non-carriers. Similarly, report having had a tubal ligation than non-carriers. no difference between BRCA1/2 carriers and non-carri-Several studies have shown an association between tubal ers were found for ever having a hysterectomy, suggest-ligation and a reduction in ovarian cancer risk [8, 17- ing that the effect of hysterectomy on ovarian cancer risk 19], although the exact mechanism remains unknown. does not differ between carriers and non-carriers.
Our results suggest that if the procedure does protect We found that OC use also appeared to be similar for against ovarian cancer, it may not provide the same both carriers and non-carriers, confirming a previous degree of protection to BRCAI carriers. This finding is report [9] . Although we did find a statistically significant in contrast to those of Narod et al. [20] who report a reduction in risk from tubal ligation among BRCA1 ential with respect to the exposures we examined, it carriers (OR = 0.39, 95%CI = 0.21-0.63, adjusted for would bias our results towards the null value. OC use, parity, history of breast cancer and ethnic About 40% of the cases included in this study were group). Data from that study were obtained from a interviewed more than one year after their diagnoses. database containing information on women from high-Women with a BRCAI or BRCA2 mutation may have risk families in Canada, the United States and the improved survival compared to women with non-hereUnited Kingdom. The differences between that study ditary ovarian cancer [22] . Therefore, it is possible that and the results presented here may be due to differences mutation carriers would be over represented among those in study populations (high-risk women with any interviewed more than a year after diagnosis. Indeed, BRCA1/2 mutation versus Ashkenazi Jewish women among those women interviewed more than one year after with one of three mutations), study design (matched diagnosis, 43% were BRCA1/2 mutation carriers; among case-control versus case-only), or chance. In particular, women interviewed within one year of diagnosis, only the BRCA1 gene has over 850 known mutations, and it 36% carried a mutation. However, this methodological is unknown whether risk factors for ovarian cancer vary issue would only impact our findings if OC use, parity, by mutation type. Confounding with other factors, such breastfeeding and/or tubal ligation affect prognosis. as family history of breast or ovarian cancer, may also An additional limitation of this study is the sample explain our findings, size, which limits the detectable differences in OC use, Care must be taken in interpreting our results. First, parity and other factors between carriers and nonsubjects were drawn from several sources. It is possible carriers, and may explain some of our negative findings. that the different study designs and data collection Finally, our choice of a case-only approach has methods could have resulted in differences among the limitations that may have affected our findings. In data sets that would affect our results. We note that particular, the case-only design assumes independence while tests for heterogeneity between BRCA status and between the genetic marker and the environmental reproductive factors revealed no significant heterogene-exposure [15] . However, it is often difficult to make this ity among subject tsource, it is possible that the tests may assessment, even in a large-scale study [10] . Hence, in the be underpowered in this instance because of the small absence of such evidence, as is the case here, point sample size and the amount of stratification needed to estimates and confidence intervals must be interpreted perform the analyses. Therefore, such a test may not be cautiously. In .particular, if there is uncertainty about very meaningful.
the assumption that OC use and parity are independent Second, we tested for a subset of mutations associated of carrier status among Jewish women, then it is possible with ovarian cancer within a well-defined ethnic popu-that the estimates reported here are less precise than the lation. This raises the question of the generalizability of data suggest [23] . The estimates may also be biased. our results to the non-Jewish population or to women Specifically, if there were a positive association between with other mutations. genotype and exposure in the underlying population, Third, three of the four sources, which provided 80 then the interaction OR above one would be biased subjects (33% of the data) for this study, tested for only towards one when compared to the ratio of relative risks the three mutations found in the Ashkenazim. Recently, that we are attempting to estimate. A case-control Frank et al. [21] reported that among 322 Ashkenazi analysis would address these limitations. Unfortunately, individuals who underwent full sequence analysis only because our data came from four sources with separate after negative results from a three-mutation test, six study designs, we lacked a valid control group to which (1.9%) carried a non-founder deleterious mutation, we could compare the distribution of risk factors found Therefore, we may have missed some mutations and among the different case groups. Moreover, because of classified some carriers as non-carriers, although in light the low prevalence of BRCA1/2 mutations in.the general of the Frank data, we would expect that number to be population, it is unlikely that we would have had less than three. Moreover, the study providing the enough carriers in any control population to employ a majority of cases [II] tested for most of the truncating standard interaction analysis. mutations in BRCA1 and BRCA2 reported to date in
In conclusion, our data suggest that in women with addition to the three founder mutations analyzed here. ovarian cancer, using oral contraceptives, bearing childNo additional mutations were found. That is, no ren and breastfeeding do not differ between women with mutations (other than the three founder mutations) were and without a BRCA1/2 mutation. While the data identified among the subjects reported here. Therefore, presented here confirm previous findings [9] , they stand the occurrence of carrier misclassification would likely be in contrast to those reported recently by Modan et al. small. Assuming that this misclassification is non-differ- [10] We also thank the anonymous reviewers, whose Three hypotheses may explain the unexpectedly similar ovarian cancer incidence rates between Israeli and American women. First, Israeli women could more often engage in protective behaviors and/or American women could more often be exposed to risk factors. This could lead to similar incidence rates due to different prevalence of known non-genetic exposures in each population. Second, risk factors might affect each population differently. That is, the relative risk for known exposures in Americans might exceed the risk attributable to that risk factor among Israelis. Together, these first two possibilities would be expected to result in higher exposure-related attributable risks among Americans. Albeit not a testable hypothesis, a final possibility is that unidentified exogenous risk factors or genetic factors may differ between Israeli and U.S. populations.
To address the testable hypotheses, we compared the magnitude and effects of known risk and protective factors for ovarian cancer between Israeli-Jewish and US Pennsylvanian women using data from two population-based case-control studies conducted in the 1990s.
MATERIALS AND METHODS

Study subjects
Subjects for the analyses presented here came from two population-based casecontrol studies undertaken in the 1990's, one in Israel (1, 5) overlooked, all the departments of gynecology in the country were monitored continually throughout the study and pathology and oncology departments were checked monthly.
Of the 1707 cases identified, 1443 (84.5%) gave consent and were interviewed. Of those not recruited, 147 (8.6%) died or were too sick to participate, and 117 (6.9%) refused to participate.
For each case, two healthy controls individually matched for age (±2 years), ethnic origin, and place and length of residence in Israel, were recruited using the Israel National Population Registry. The use of this registry ensured that women invited to participate as controls, were representative of the general population. About 67% of all women asked to participate as controls agreed, achieving a total of 2384 controls. To ensure comparability between studies, and because the age range within the U.S. study was 20-69, this age range restriction was applied to the Israeli data. Thus, this analysis is based on 998 epithelial ovarian cancer cases and 1528 controls.
In the American Study, cases were women age 20-69 diagnosed with incident epithelial ovarian cancer within the six months prior to interview. Between May 1994 and July 1998, 873 eligible women were identified at 39 hospitals around the Delaware
Valley. Fourteen physicians did not consent to their patients' participation and 92 women refused to participate. Thus, our analyses are based on the 767 completed case interviews (88% of potentially eligible incident cases). The diagnosis of epithelial ovarian cancer was confirmed by pathology in all cases.
Controls aged 65 or younger were ascertained by random digit dialing and frequency matched to cases by 5-year age groups and three digit telephone exchanges.
Of the 14,551 telephone numbers screened for this purpose, we identified 1,637
households with a potentially eligible control, of whom 1215 (74%) completed interviews.
Controls aged 65-69 were ascertained through Health Care Financing Administration (HCFA) lists. Of the 263 potentially eligible participants identified, 152 (58%) were interviewed. Therefore, of the 1,900 screened and potentially eligible controls, 1,367 (72%) are included in these analyses.
Data collection
In Israel, face to face interviews were conducted by a group of experienced, multilingual, trained interviewers, and when needed, the interview was conducted in the native language of the respondent. Cases were interviewed in the hospital, typically four to six days after gynecologic surgery. Controls were interviewed at home by the same highly trained staff that interviewed the cases.
In the American study, a standardized 1.5-hour in-person interview of cases and controls was conducted at the subject's home. In both studies, detailed information was obtained on demographic, anthropometric, lifestyle, hormonal, medical, as well as personal and family history of cancer. Extensive gynecologic and obstetric histories were also obtained. A life calendar, marked by important happenings that participants recalled during their lives, was used to enhance memory of distant events.
Statistical methods
Within each population, frequencies were calculated for demographic variables as well as for potential ovarian cancer risk and protective factors such as: family history of ovarian and breast cancer, reproductive variables, contraceptive and hormonal use, gynecological variables and body mass index (BMI) (weight in kilograms/height in meters 2 ). Chi-squared tests were used to test for significant differences in the frequencies of categorical risk/protective factors and t-tests for statistical differences in continuous risk/protective factors between Israeli and American controls.
Due to the different matching design of the two studies, the individual matching of the Israeli study was broken and an unmatched analysis was performed. Odds ratios with corresponding 95% confidence intervals were calculated as the primary measure of effect size using univariate unconditional logistic regression with adjustment for age, education and ethnic origin/race. Variables that were significant in the univariate analysis or that were considered important biologically were entered into multivariate logistic regression analyses. Odds ratios between the two study populations were compared using Wald's Test. Population attributable risks were calculated for each variable using the methods described by Benichou for evaluating attributable risk for categorical and continuous variables (9) . Confidence intervals for the attributable risks were calculated using the methods given by Greenland (10). Table 1 shows the distribution of variables with known risk/protection for ovarian cancer among Israeli and U.S. controls. Significant differences (all at a level of p<0.001)
RESULTS
were detected for most of these factors between the two groups. With respect to reproductive variables, Israeli women reported a later age at menarche, greater number of live births and proportion of women who ever gave birth, higher percentage of breastfeeding among parous women, longer duration of breastfeeding among ever breast feeders, and later age at menopause. With respect to contraception and use of hormones, Israeli women were significantly more likely to use an IUD (37% vs. 16.7%);
and less likely to have a tubal ligation (3% vs. 33%), to use oral contraceptives (28.3%
vs. 68.7%), and to take hormone replacement therapy (12.1% vs. 33%). Hysterectomy and use of talc were more prevalent in the US. Surprisingly, Israeli women were significantly less likely than U.S. women to report a family history of both breast (6.2% vs.
10.0%) and ovarian neoplasms (0.8% vs. 2.0%). Body mass index at age 18 was higher by an average of 0.6 units in Israeli women (p<0.001).
In both Israel and the U.S., the main histologic subgroup for the cases was serous (40.3% in Israel, 36.5% in the U.S.) (data not shown). This was followed by endometrioid tumors (13.0% versus 17.7%) and mucinous tumors (4.0% versus 6.8%). Other non- No other odds ratios differed significantly between the two populations. In both populations, family history of ovarian cancer was the strongest risk factor (OR=6.17 and 3.17 for Israel and the US, respectively) and did not differ between populations (p=0.15).
Family history of breast cancer was a significant risk factor only in the Israeli population (OR=1.54) but was not significantly different between populations. In both groups, a nonsignificant protective effect was observed for hysterectomy and IUD use. Tubal ligation was protective and talc use a risk factor in both groups but only significantly so in the American group. Hormone replacement therapy use was not a risk factor in the US population, and was associated with a 28% increased risk of borderline significance in the Israeli population. Age at menarche was not associated with ovarian cancer in either population.
The top three factors contributing to the PAR among Israelis and Americans were relatively similar (Figure 2 ). For Israelis, it was lack of hysterectomy, lack of tubal ligation, and fewer than 10 years of oral contraceptive use. For Americans, it was fewer than 10 years of oral contraceptive use, lack of tubal ligation, and fewer than three live births.
Significant differences in the magnitude of the population attributable risks between the groups were noticed for live births and talc use which were both more pronounced in the American group. Although non significantly different from the Israeli group, the PAR of not breastfeeding, not going through tubal ligation, not using IUD and using OC for less than 10 years, were greater in the American group.
DISCUSSION
In the case-control studies from Israel and the U.S. presented here, Americans, on the whole, had a greater prevalence of contraceptive protective factors including oral contraceptives and tubal ligation. Lack of these same protective factors were among the three top contributors to the PAR in both populations, but more so for Americans. In other words, American women tended to be more protected by these known exposures than Israeli women. This is surprising and opposite to our a priori hypotheses that
Israelis would have a greater frequency or a greater protection from exogenous factors, thereby countering their excess genetic risk and accounting for the similarity in overall ovarian cancer incidence between U.S. and Israeli populations.
Reassuringly, our data generally confirm the risk and protective factors previously reported to be associated with ovarian cancer. Oral contraceptives are considered to be the most powerful known chemopreventative agents for ovarian cancer with longer use affording greater protection (11) (12) (13) . Parity has been shown to be protective for ovarian cancer in a plethora of studies with first birth affording the greatest protection and each additional birth adding to the protection (13) (14) (15) (16) (17) family members with breast cancer in this study could cause an overestimation of familial aggregation because breast cancer is so common (6) . That is, family cases among older relatives are likely to occur by chance and may not necessarily suggest a familial cluster.
Therefore, it is not entirely appropriate to consider family history as a proxy for BRCA1/2
carriage. Nonetheless, we observed a substantial increase in risk associated with a family history of ovarian cancer in both populations.
Another limitation of our study is lack of information about other putative risk/protective factors for ovarian cancer. For instance, we do not have comparable data on non-steroidal anti-inflammatory medications or diet. However, to date, studies have not consistently shown an association between these factors and ovarian cancer (22) (23) (24) (25) .
A final limitation is the lack of standardization in questionnaire design and implementation between the two studies. Although the questions asked were very similar, they were not identical and although questionnaires were delivered by trained interviewers, the training was not common to the two studies. Therefore, methodologic differences between the studies may confound our results.
Given that we could not explain the similar rates of ovarian cancer between
Israelis and Americans despite the greater genetic predisposition on the part of the former group, we must consider other explanations. The most apparent of these is the existence of undiscovered gene-gene and gene-environment interactions. It is likely that other genes affect ovarian cancer risk; each of these probably has a lower penetrance than BRCA, and each probably accounts for a smaller portion of ovarian cancer risk.
Nonetheless, these might potentially account for some of the risk among American nonJews. Exposures not measured in this study and not clearly related to ovarian cancer may also explain the surprisingly low rate of ovarian cancer among Israelis. In particular, whereas 36% of Ashkenazi Jewish women with epithelial ovarian cancer in Israel will carry a mutated BRCA1/2 gene (5), over 45% of Jewish American women with ovarian cancer will be carriers (14) . The greater penetrance of BRCA1/2 in the US supports the existence of an unidentified environmental or lifestyle factor. For example, because of its lower latitude, sun exposure is greater in Israel than in Pennsylvania, suggesting that Vitamin D exposure may be protective against ovarian cancer, just as it may be for other hormonally-linked cancers including breast (26) and prostate (27) cancers. Notably, in the US ovarian cancer mortality declines as one moves from north to south (28) and international data for westernized countries suggests a similar latitude-related trend in ovarian cancer incidence (6) . Moreover, ecological studies in the US have shown an inverse association between sunlight exposure and ovarian cancer mortality, (29, 30 
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